TAK 931

Drug Profile

TAK 931

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 25 Oct 2017 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03261947)
  • 25 Oct 2017 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03261947)
  • 29 Aug 2017 Millennium Pharmaceuticals plans a phase II trial for Pancreatic cancer and Colorectal cancer (Metastatic disease) (NCT03261947)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top